AzTrials
AzTrials

Adolescent Idiopathic Scoliosis (AIS)MID-CNCT03071445

Feasibility Study of MID-C for AIS

An observational study of Adolescent Idiopathic Scoliosis (AIS), run by Apifix at 3 sites in 2 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Adolescent idiopathic scoliosis (AIS) is a common disorder of unknown etiology in which the vertebrae and discs gradually develop a curvature that is first detected in patients between 11 and 20 years of age. The deformity is 3-dimensional, with a coronal curve measured from radiographs by the Cobb angle . Read more about this study

Who is it for?
Ages 11 to 20 years
Conditions the study is for
Adolescent Idiopathic Scoliosis (AIS)
How many people
13 participants
Where
3 sitesin 2 countries
Study dates
Apr 2012to Apr 2016
How long will I take part?
2 Years
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 11 to 20 years
  • All sexes
  • No healthy volunteers
  • Child, Adult

Study population: The study is designed as a prospective, non randomized, open label study with a 24-month follow-up period. Consecutive patients undergoing treatment of AIS by the MID-C system will be included during a 1-years enrollment period.

Who may be able to join

  • Adolescence above and inclusive 11 years old
  • Minimum of 35 degrees Cobb angle, confirmed by X-ray. Lenke type 1 or 5
  • Completed at least 6 months of conservative therapy (e.g., P.T., bracing, traction, or others).
  • Reisser sign of 2 to 4
  • Appropriate candidate for posterior surgical approach
  • Subject has Good general health.
  • Subject has no hypersensitivity and allergies to Titanium
  • Subject guardians willing to sign a written informed consent form (ICF).surgeon

Who cannot join

  • Cobb angle over 55 degrees
  • Other non idiopathic scoliosis.
  • AIS which is not defined as Lenke type 1 or 5
  • Previous spine surgery.
  • Allergy to any component of the device.
  • Active systemic disease, such as AIDS, HIV, or active infection
Show all 9Show fewer
  • Back or leg pain of unknown etiology
  • Systemic disease that would affect the subject's welfare or overall outcome of the study.
  • Mentally compromised

Trial locations and contacts

3 sites in 2 countries.

3 sites in 2 countries

Romania2 sites
  • Maria Sklodowska Curie

    Bucharest

  • Spitalul de Copii Sf. Maria

    Iași, Romania

Other trials in Romania

Hungary1 site
  • University of Pecs

    Pécs, H-7632

Other trials in Hungary

About this study

Official title: Safety and Effectiveness Evaluation of the Minimal Invasive Deformity Correction (MID-C) System in Adolescent Idiopathic Scoliosis (AIS)

Adolescent idiopathic scoliosis (AIS) is a common disorder of unknown etiology in which the vertebrae and discs gradually develop a curvature that is first detected in patients between 11 and 20 years of age. The deformity is 3-dimensional, with a coronal curve measured from radiographs by the Cobb angle .

The Cobb angle measurement of scoliosis represents the sum of the angular wedging of each vertebra and disc between the superior and inferior end vertebrae . Although a small curve is well tolerated and does not require treatment, a large curve can progress to the point that it is cosmetically unacceptable, interferes with chest wall mechanics, and produces cardiac and pulmonary compromises. The natural history of AIS apparently includes 2 stages: the initiation of the curve and its subsequent progression. The factors responsible for the initiation of the curve are unknown, but the subsequent progression of the curve is clearly associated with the adolescent growth spurt . The primary risk factors for progression include age at onset and the magnitude of the curve; young patients with large curves are at the highest risk .

Read more

Although numerous treatment methods have been recommended for patients with AIS, the only accepted treatment includes bracing for skeletally immature patients with curves between 25 and 40 degrees and operative correction with spinal fusion for patients with curves greater than 45 degrees. For many teenagers, the cosmetic and social concerns associated with bracing has caused compliance problems with wearing the brace and many patients only wear the brace at home . While operative intervention completely corrects the scoliosis or rib hump, it eliminates segmental spinal motion, and concentrates stresses at the ends of the fusion potentially leading to disc degeneration and back pain.

Despite satisfactory short-term results of operative instrumentation and fusion, a less invasive technique preserving more motion with a smaller scar represents a major improvement. Realizing this goal is contingent on treating curves early, before they progress to an irreversible deformity, and when there is still enough residual growth and remodeling potential.

ApiFix Ltd has developed a novel implant for less invasive treatment of AIS. The MID-C system is designed to correct the deformity step by step along a period of time, giving the skeletal and soft tissues time to accommodate any incremental correction.

The MID-C System inherent benefits are:

  • Only two screws are used
  • Incision size is much smaller
  • Simpler operation with shorter operative time
  • Less complications (attributed to the three points above).
  • Minimal spinal mobility loss.

All the device components are made of materials well accepted in the orthopedic field and are fully biocompatible (see Investigator Brochure).

The unique concept of the system and the materials used may provide favorable results as follows: Smaller scare, quicker healing period and better spine mobility over the years.

This study is designed to demonstrate that the MID-C System is safe and effective.

Read the detailed description

The study is designed as an observational study with a 24-month follow-up period. Consecutive patients undergoing treatment of AIS by the MID-C system in daily practice will be included during a 1-year enrollment period.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. No Device related Serious Adverse Event

    Measured: 2 years

  2. No significant curve progression above or below the implant

    Measured: 6 months, 1 year, 2 years

Secondary outcomes (2)
  1. Minimum of 50% deformity correction within 6 months

    Measured: 6 months

  2. Evaluate the correction period using X-ray

    Measured: 2 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted7 Mar 2017
  2. Study startApr 2012
  3. Primary completionApr 2016
  4. Study completionApr 2016

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
13 participants (actual)
Target duration
2 Years
IDs, dates and publications
ClinicalTrials.gov ID
NCT03071445
Sponsor's protocol ID
AF-01
Acronym
MID-C
Status last verified
Feb 2017
First submitted
26 Feb 2017
Last updated
7 Mar 2017
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Adolescent Idiopathic Scoliosis (AIS), run by Apifix at 3 sites in 2 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 7 Mar 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 3 sites in Romania, Hungary. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

No Device related Serious Adverse Event (time frame: 2 years). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Mar 2017; AzTrials last refreshed its copy on 26 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in